[Skip to Navigation]
Sign In
Comment & Response
May 9, 2019

Guidelines for Secondary Solid Cancers Among HSCT Recipients—In Reply

André Tichelli, MD1; Gérard Socié, MD2; Nina Salooja, MD3; et al for the Transplant Complications Working Party of the EBMT
Author Affiliations
  • 1Department of Hematology, University Hospital, Basel, Switzerland
  • 2Department of Hematology–BMT, Hôpital St Louis, Paris, France
  • 3Center for Haematology Imperial College, London, United Kingdom
JAMA Oncol. 2019;5(7):1064-1065. doi:10.1001/jamaoncol.2019.0636

In Reply We thank Vasco and Napoli for their interest in our work1 and for their comments regarding the value of guidelines for the screening of and preventative care for secondary solid cancers among hematopoietic stem cell transplant (HSCT) recipients. Our study investigated the outcome of secondary cancers after HSCT and in this regard it was similar to the study by Inamoto et al.2 Neither study was specifically designed to investigate risk factors for secondary solid cancers in this patient population or to evaluate the effectiveness of current screening programs. As such, more work is required on this important topic. Both studies were based on large data sets, however, and have demonstrated that some cancers, such as colon, respiratory, and prostate cancers, are more common in posttransplant populations than previously reported. These secondary solid cancers certainly need to be reevaluated with special attention paid to risk factors in the HSCT population compared with the general population. These new data highlight the need for regular updates to guidelines on this topic.

Add or change institution